Tag
A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.
Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.
这项随机试验表明，艾曲波帕显著改善了新诊断为ITP的儿童的持续血小板反应，提供了一种潜在的早期干预选择。
This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.
This phase III trial evaluated oral valiltramiprosate in APOEε4/ε4 homozygotes with early Alzheimer’s, showing brain atrophy slowing but limited overall clinical benefit, with nominal improvements in mild cognitive impairment subgroup
The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.
This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.
This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.
The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.
The IMPROVE-multi randomized clinical trial found that tailoring perioperative blood pressure targets to individual preoperative nighttime MAP levels did not reduce postoperative organ injury or mortality compared to routine management in h
In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.
The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.
A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.
Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies
This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson’s disease patients previously stable on continuous DBS.
Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.
The MACRO trial demonstrates that endoscopic sinus surgery significantly improves quality of life in adults with chronic rhinosinusitis, while long-term low-dose clarithromycin shows no added benefit over placebo.
The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, high
A multi-center, triple-blind phase 2 trial demonstrates that daily candesartan 16 mg significantly reduces migraine days in episodic migraine patients, with tolerable safety profiles, supporting its role as an effective preventive option.
The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the
